Le Lézard
Classified in: Health
Subjects: NPT, TRI

Rare Disease Foundation Announces First Global Registry


SAN FRANCISCO, Aug. 29, 2018 /PRNewswire/ -- Today the Grace Science Foundation ("GSF") announced the creation of the world's first and only NGLY1 Deficiency registry, which provides invaluable resources to the medical community racing to find a cure for this rare genetic disorder. So far, the registry contains a treasure trove of data on 36 patients' genomes, symptoms, medical and treatment history, furthering the collaborative efforts GSF founders Kristen and Matt Wilsey have put at the forefront of GSF's initiatives.

NGLY1 families from four countries enroll in the NGLY1 Registry in Palo Alto, California.

"The registry enables clinicians to identify successful interventions in other patients and provides data to researchers looking for clues to support new hypotheses," noted Kristen Wilsey. "This will help accelerate the development of therapies for NGLY1 patients who experience debilitating symptoms."

NGLY1 Deficiency is a genetic disorder that affects many body systems, causing seizures, delayed development, movement abnormalities, liver dysfunction, eye abnormalities, and a reduction or absence of tears. The disorder is rare, with only 49 known living patients, making collaboration amongst researchers in varying parts of the world critical in order to hasten progress toward a treatment. The NGLY1 Deficiency registry streamlines data so researchers everywhere can make informed decisions based on real-time feedback and information. "Knowing patient history, disease progression, and current health status is essential," says Dr. Carolyn Bertozzi at Stanford University. "We have used the registry several times and it's been incredibly valuable. Without question the data have accelerated our understanding and will help the team develop therapies that are more effective."

This groundbreaking platform is part of GSF's pioneering approach modeled after the Silicon Valley startup model, explained Matt Wilsey, "In the face of limited funds and a short timeline, we're bringing together top talent and dropping them in a fast-paced, collaborative environment that is highly iterative."

The Grace Science Foundation is a not-for-profit organization, whose mission is to cure NGLY1 Deficiency by pioneering approaches to scientific discovery that are faster, less expensive and more collaborative. For more information, visit the Grace Science Foundation registry page.

 

SOURCE Grace Science Foundation


These press releases may also interest you

at 08:16
On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds"). Pursuant to the terms and...

at 08:07
On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA)...

at 08:05
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will...

at 08:05
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 10,...

at 08:05
Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in the following upcoming...

at 08:05
$16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results in the wind down of the PUR1900 Phase 2b study and allows for a significant...



News published on and distributed by: